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REVIEW
Abstract: Cardiovascular (CV) disease remains the number 1 cause of death in the USA.
Nonetheless, there has been a decline in the age-adjusted death rate for coronary heart disease
(CHD) which may be due to more aggressive treatment guidelines for treating CV risk factors,
such as hypertension, diabetes, and dyslipidemia. The recent update to the National Cholesterol
Education Program (NCEP) guidelines have recommended lower low-density lipoprotein
cholesterol (LDL-C) goals in high-risk patients. Based on the new targets for LDL-C, clinicians
will need more efficacious lipid-lowering therapies. One of these newer therapies is the
combination of ezetimibe and simvastatin. This article reviews the implications of the updated
guidelines and discusses the efficacy and safety of ezetimibe/simvastatin for lowering LDL-C.
Keywords: statin, ezetimibe, combination lipid treatment
Introduction
Coronary heart disease (CHD) remains the number 1 cause of death in the USA.
Over the past 2 decades, the age-adjusted death rate for cardiovascular (CV) disease
has declined by over 50% (Morbidity and Mortality 2002). This decline is due in
part to an increased awareness and implementation of evidence-based guidelines for
treating multiple CV risk factors, in particular, hypertension (Chobanian et al 2003),
diabetes (ACE 2002), and dyslipidemia (NCEP 2001). Along with these guidelines,
therapeutic options for treating hypertension, diabetes, and dyslipidemia have
improved, making it easier to reach target goals for blood pressure control, diabetes
management, and cholesterol lowering.
While some of the therapeutic advances have entered the market as new drug
classes, many new therapies have been created by combining established drugs to
produce greater efficacy. These drug combinations offer clinicians the ability to
achieve target goals at lower dosages of each drug. For instance, when treating
hypertension, the combination of a low dose of an angiotensin-converting enzyme
(ACE)-inhibitor, plus a low dose of a diuretic, lowers blood pressure more effectively
than a higher dose of either one of these agents alone. Lower doses of two agents in
a single drug also have the potential to reduce the side-effect profile, the cost of
therapy, and to improve patient compliance by reducing the total pill burden.
The concept of combination therapy, which already provides better control of blood
pressure and more recently, diabetes, has now entered the arena for treating
dyslipidemia. The first combination therapy for treating dyslipidemia was the
lovastatin/niacin extended-release (ER) combination (Advicor
®). This drug produced
enhanced lowering of both low-density lipoprotein cholesterol (LDL-C) and tri-
glycerides, as well as significant increases in high-density lipoprotein cholesterol
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(HDL-C) (Kashyap et al 2002). Several clinical trials have
also suggested niacin can improve CV endpoints when added
to statin therapy (Brown et al 1998, 2001). Despite its efficacy,
this therapy has not been widely embraced by clinicians,
largely due to intolerance with the niacin component.
Recently a new combination therapy for treating
dyslipidemia was approved by the US Food and Drug
Administration agency. This lipid-lowering therapy (LLT)
combines ezetimibe (Zetia
®), a cholesterol absorption
inhibitor, with simvastatin (Zocor
®), one of the most
clinically studied statins for CV risk reduction. This
combination (Vytorin
®) has been shown to significantly
enhance LDL-C lowering over statin monotherapy, and
improve attainment of evidence-based LDL-C goals
(Ballantyne et al 2004; Goldberg et al 2004). This review
will discuss the rationale for the more intensive LDL-C goals
from the National Cholesterol Education Program (NCEP),
and the clinical data supporting the efficacy and safety of
the ezetimibe/simvastatin combination.
The challenge ahead
While the risk of age-adjusted CHD death is declining, the
total number of CHD-related deaths remains high. There
are more than 1 million deaths due to CHD annually and
there were approximately 1.7 million acute coronary
syndromes (ACS) (AHA 2002). Several epidemiologic
trends have continued to fuel the high rate of CHD. From
1991 to 2001, the prevalence of multiple CHD risk factors
have significantly increased. The prevalence of hypertension
increased by 11.9%, diabetes by 46.5%, obesity by 64.7%,
and dyslipidemia by 14.2% (CDCP 2004).
It is estimated that approximately 50 million Americans
have hypertension, 10–12 million have diabetes, and more
than 100 million have dyslipidemia (AHA 2004). Diabetes
is now considered a CHD risk equivalent (NCEP 2001).
Moreover, diabetes significantly increases the risk of CV
events 3–4 fold when combined with any other risk factor
(Beckman et al 2002). Because of this increased prevalence
of CHD risk factors, more intensive treatment of at-risk
patients is needed to prevent more CV events.
The metabolic syndrome represents a clustering of CV
risk factors that may be the result of insulin resistance,
although the exact cause is not known. The diagnostic
criteria for the metabolic syndrome are abdominal obesity
(increased waist circumference), low HDL-C, and high
triglycerides, as well as hypertension and impaired fasting
glucose. According to the Adult Treatment Panel III (ATP
III), patients with the metabolic syndrome have a high risk
for CV disease, and may be considered for an optional
LDL-C goal of < 100 mg/dL (NCEP 2001).
The clinical evidence supporting LLT with statins is
overwhelming. Statins have been shown to effectively reduce
LDL-C, to have a highly favorable risk–benefit ratio, and to
lower CV events by 25%–40%. It is estimated that if statin
therapy were implemented for all high-risk patients in the
USA, approximately 67 000 coronary deaths, 78 000 strokes,
117 000 nonfatal myocardial infarctions, and 146 000
revascularization procedures would be prevented per year
(Ballantyne, O’Keefe, et al 2005). This means that for every
physician managing 1000 high-risk patients, statin use could
prevent one CHD death, myocardial infarction, or stroke
every 12 days.
National Cholesterol Education
Program guidelines (ATPIII): new
clinical data supports intensive
LDL-C treatment
The ATP III guidelines were released in May 2001 (NCEP
2001). While ATP III reemphasized the same CHD risk
factors as ATP II, the major shift was to focus on the global
risk of the patient. Several distinctions were made with
regards to optimal LDL-C goals and patient risk categories.
An LDL-C level of < 100 mg/dL was established as the
optimal LDL-C level and patients with the diagnosis of CHD,
or CHD risk equivalents, were candidates for this goal. ATP
III defined three patient groups as CHD risk equivalents:
(1) diabetes mellitus (removed as a risk factor in ATP II);
(2) noncoronary atherosclerosis (such as peripheral artery
disease, abdominal aortic aneurysms, or symptomatic
carotid artery disease); and
(3) patients with multiple risk factors that confer a 10-year
CHD risk of greater than 20%. (Table 1).
Since 2001, several new statin clinical trials have been
completed, which evaluated their impact on CV endpoints
in more than 60 000 patients and formed the basis for an
update to ATP III in 2004 (Grundy et al 2004). The five
major outcomes trials considered in the ATP III update are:
(1) The Heart Protection Study (HPS) (HPS 2002);
(2) Prospective Study of Pravastatin in the Elderly at Risk
(PROSPER) (Shepherd et al 2002);
(3) Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT-LLT) (ALLHAT
2000);
(4) Anglo-Scandinavian Cardiac Outcomes Trial–Lipid
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(5) Pravastatin on Atorvastatin Evaluation and Infection
(PROVE-IT) (Cannon et al 2004).
The Collaborative Atorvastatin Diabetes Study (CARDS)
(Colhoun et al 2004) was published soon after the update;
but will be discussed here. Most of these subjects were high-
risk primary prevention, with the exception of the PROVE-
IT and a subgroup of the HPS. All were comparisons of a
statin vs placebo, except for PROVE-IT, which compared
two statins.
Heart Protection Study
The HPS was a randomized, double-blind, placebo-
controlled 5-year trial of 20 536 high-risk adults, comparing
simvastatin 40 mg to placebo. Simvastatin significantly
reduced all-cause mortality by 13% (p = 0.0003) and major
coronary events (nonfatal myocardial infarction and
coronary death) by 24% (p < 0.0001). More importantly,
HPS was able to demonstrate a benefit with statin therapy
regardless of baseline LDL-C level, particularly in those
subjects with LDL-C < 100 mg/dL.
Prospective Study of Pravastatin in the
Elderly at Risk trial
The PROSPER trial was a randomized, placebo-controlled
trial of 5804 older high-risk patients, with or without known
CHD, between the ages of 70–82 years old who were assigned
to either pravastatin 40 mg or placebo. Over 3.2 years, there
was a 15% (p = 0.014) reduction in combined clinical
endpoints and a 24% (p = 0.043) reduction in CHD mortality.
Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial
– Lipid Lowering Trial
The ALLHAT-LLT randomized 10 355 hypertensive
patients, age 55 and older with total cholesterol < 250 mg/dL
to pravastatin 40 mg or usual care for 5 years. The LDL-C
reduction in the pravastatin group was 28% compared with
11% in the usual care group and there was a nonsignificant
difference in major cardiac events. ALLHAT-LLT was the
first major statin clinical trial to not show a statistically
significant benefit in reduction of CV events. The
investigators attributed this result to the small difference in
the LDL-C levels between the treatment group (LDL-C
104 mg/dL) and the usual care group (LDL-C 122 mg/dL).
While there was no benefit in the overall population, the
African American subgroup did have a significant 24%
reduction in CV events.
Anglo-Scandinavian Cardiac Outcomes
Trial – Lipid Lowering Arm trial
The ASCOT-LLA randomized more than 10 000 patients
with hypertension and 3 or more risk factors, and a total
cholesterol ≤ 250 mg/dL to atorvastatin 10 mg or placebo.
While the trial was planned for 5 years, it was terminated at
3.3 years because of a 27% reduction (p = 0.024) favoring
atorvastatin in the primary endpoint. The LDL-C reduction
with atorvastatin was 34% (mean LDL-C 90 mg/dL) vs 4%
with placebo (mean LDL-C 126 mg/dL). As in HPS, there
was evidence of clinical benefit across the baseline
cholesterol levels, including those with total cholesterol
< 194 mg/dL.
Pravastatin on Atorvastatin Evaluation
and Infection Trial
The PROVE IT trial randomized 4162 patients with ACS to
receive either intense therapy with atorvastatin 80 mg vs
moderate therapy with pravastatin 40 mg. The intensive
therapy group achieved a LDL-C of 62 mg/dL at 2 years
while the moderate therapy group achieved a LDL-C of
95 mg/dL. The intensive therapy group had a 16% reduction
(p < 0.005) in the composite end point. This study
demonstrated that more intensive LDL-C lowering initiated
at the time of ACS reduced CV events better than less
intensive therapy, with good tolerance.
Cardiovascular Atorvastatin Diabetes
Study trial
The CARDS study was a planned 6-year, randomized,
double-blind, placebo-controlled trial of 2383 patients
with a history of Type II diabetes and average LDL-C
level (baseline 119 mg/dL in the treatment group and
118 mg/dL in the placebo). Patients were randomized to
atorvastatin 10 mg or placebo. The trial was stopped at
Table 1 ATPIII Guidelines 2001: CHD and CHD risk
equivalents – target LDL-C < 100 mg/dL
￿ CHD
￿ Diabetes mellitus
￿ Noncoronary atherosclerosis
– Peripheral artery disease
– Abdominal aortic aneurysm
– Symptomatic carotid artery disease
￿ Multiple risk factors > 20% CHD risk at 10 years
Abbreviations: CHD, coronary heart disease; LDL-C, low-density lipoprotein
cholesterol.Vascular Health and Risk Management 2006:2(1) 34
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3.9 years due to a 37% reduction (p = 0.001) in CV events.
The mean on-treatment LDL-C was 82 mg/dL, and patients
who were above or below the baseline mean had similar
clinical benefit from active treatment.
Treat to New Targets trial
The Treat to New Targets (TNT) trial compared atorvastatin
10 mg with atorvastatin 80 mg in 10 001 patients with CHD
for 5 years (LaRosa et al 2005). Patients on atorvastatin
10 mg achieved a LDL-C of 101 mg/dL while those on
atorvastatin 80 mg achieved a LDL-C of 77 mg/dL. There
was an overall 22% reduction in major CV events with more
intensive compared with less intensive therapy. These
clinical trial data, along with HPS and PROVE-IT, provide
strong evidence that lower LDL-C is better in high-risk
patients.
ATP III addendum – the new
optional LDL-C goal
The results of these trials in high-risk primary and secondary
prevention patients confirm that clinical benefit occurs with
more intensive lowering of LDL-C levels. The ATP III
addendum has therefore recommended an optional LDL-C
goal of less than 70 mg/dL for very high-risk patients, and
an optional goal of less than 100 mg/dL for moderate to
high-risk (10% to 20% 10-year CHD risk) patients (Grundy
et al 2004). The very high-risk patient category is defined
as established CHD plus one of the following: (1) diabetes
mellitus; (2) severe or poorly controlled risk factors (ie,
cigarette smoking, hypertension, or hyperlipidemia); (3)
multiple risk factors associated with the metabolic
syndrome; or (4) acute coronary syndrome (Table 2).
Consistent with this recommendation and the results of the
randomized clinical trials, the ATP III Update has stated
that statin therapy is first line treatment and that the dose of
the statin should lower LDL-C by at least 30%–40%. Table 3
lists the therapeutic options available with statin mono-
therapy to achieve 30%–40% LDL-C lowering.
Since the prevalence of CV risk is increasing and new
clinical trials confirm reducing LDL-C to lower targets
improves outcomes, more efficacious therapies are needed
to successfully achieve these goals. New statins with greater
LDL-C efficacy (Jones et al 2003) and new combination
therapies improve the ability to reach new LDL-C targets.
The most recent update from the National Health and
Nutrition Examination Survey III (NHANES III) suggests
that only 16% of CHD patients reach an LDL-C level of
< 100 mg/dL and that more than 60% of CHD patients are
not currently on LLT (NHANES 1999). Furthermore,
NHANES III notes that the average LDL-C level for a CHD
patient is 133 mg/dL. Therefore, for the average CHD patient
to achieve a LDL of < 100 mg/dL, a statin dose that lowers
LDL-C by 25%–30% is needed. For those at very high-risk
with an optional LDL-C goal of < 70 mg/dL, a statin dose
that reduces LDL-C by 45%–50% is required.
To reach 50% LDL-C reduction efficacy, clinicians must
prescribe moderate to high doses of the one of three most
efficacious statins, which are atorvastatin, simvastatin, and
rosuvastatin. Atorvastatin can reduce LDL-C by 45%–50%
at the 40 mg to 80 mg dose, while simvastatin at the 80 mg
dose, and rosuvastatin at 10 mg and 20 mg doses, have
similar efficacy (Jones et al 2003). For many clinicians,
however, there are safety and tolerability concerns about
using the highest doses of a statin. Except for these three
statin monotherapies doses, combination therapy is
necessary to reduce LDL-C by 45%–50% or greater.
Table 2 NCEP ATP III addendum: optional LDL-C goal
< 70 mg/dL for the very high-risk patient
CHD plus:
1. Diabetes mellitus;
2. Severe or poorly controlled risk factors (ie, cigarette smoking,
hypertension, or hyperlipidemia);
3. Multiple risk factors associated with the metabolic syndrome; or
4. Acute coronary syndrome.
Abbreviations: ATP III, Adult Treatment Panel III; CHD, coronary heart disease;
LDL-C, low-density lipoprotein cholesterol; NCEP, National Cholesterol
Education Program.
Table 3 Therapeutic options for achieving a 30%–40%
reduction in LDL-C
Dose LDL-C
Drug (mg/dL) reduction (%)
Atorvastatin 10* 39
Fluvastatin 40–80 25–35
Lovastatin 40* 31
Pravastatin 40* 34
Rosuvastatin 5–10
+ 39–45
Simvastatin 20–40* 35–41
Abbreviations: LDL-C, low-density lipoprotein cholesterol.
*Available at doses up to 80 mg/dL; doubling of dose will produce an additional
6% decrease in LDL-C.
+ Available at doses up to 40 mg/dL; doubling of dose will produce an additional
6% decrease in LDL-C
Grudy SM, et al. 2004. For the coordinating committee of the NCEP. Circulation,
110:227–39.Vascular Health and Risk Management 2006:2(1) 35
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A unique perspective for
cholesterol lowering: the
ezetimibe and simvastatin
combination
Ezetimibe offers a unique mechanism of action not available
in any other LLT (Figure 1). It blocks cholesterol transport
at the level of the proximal small bowel (Van Heek et al
2000). Recent work by Altmann et al (2004) has revealed
that the Nieman-Pick C1 Like 1 protein is critical for the
update of cholesterol across the plasma membrane of the
intestinal enterocyte. Ezetimibe inhibits approximately 54%
of intestinal cholesterol, which is predominately derived
from biliary excretion, before it can be incorporated into
chylomicrons. This effect decreases the cholesterol ester
(CE) content in chylomicrons as they enter into the plasma,
which results in reduced delivery of cholesterol to the liver,
causing an upregulation of LDL-C receptors and increased
clearance of LDL-C from the plasma. Ezetimibe is absorbed,
undergoes glucuconidation in the liver, and is excreted in
bile, where it returns to the intestinal lumen and continues
to inhibit cholesterol absorption. There is minimal systemic
exposure. In clinical trials evaluating ezetimibe efficacy,
monotherapy at 10 mg was found to lower LDL-C by 17%
(p < 0.01 compared with placebo) (Knopp et al 2003). The
safety and tolerability was found to be comparable with
placebo, specifically with respect to hepatic transaminases
and creatine kinase (CK) levels.
Statins inhibit the rate-limiting step of cholesterol
synthesis by competitively inhibiting HMG CoA reductase
in the liver. The inhibition reduces the hepatic cholesterol
pool, which causes an upregulation of LDL-C receptors on
the hepatic surface and enhanced removal of LDL-C
particles from the plasma. Since ezetimibe also reduces the
hepatic cholesterol pool by decreasing the return of intestinal
cholesterol, it would appear that this action should be
complimentary to that of statins.
The chemical name of ezetimibe is 1-(4-fluorophenyl)-
3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-
hydroxyphenyl)-2-azetidinone (Figure 2a). The empiric
formula is C24H2F2NO3. Simvastatin is butanoic acid, 2,2-
dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-
hexadryro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxyl-6-
oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester. The
empiric formula of simvastatin is C25H38O5 (Figure 2b).
Figure 1 A schematic for sites of action of cholesterol-lowering agents, ezetimibe and simvastatin.
Abbreviations: CE, cholesterol ester; CM, chylomicron; CMr, chylomicron remnant; EZE, ezetimibe; IDL, intermediate density lipoprotein; LDL, low density
lipoprotein; LDLr, low density lipoprotein receptor; VLDL, very low density lipoprotein; SIM, simvastatin; TG, triglyceride.
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As expected, several clinical trials have documented the
enhanced LDL-C efficacy of the ezetimibe/simvastatin
combination over statin monotherapy (Table 4). The
Ezetimibe Study Group reported that coadministration of
ezetimibe/simvastatin was more effective than simvastatin
alone (p < 0.001) in reducing LDL-C levels (Goldberg et al
2004). Ballantyne et al (2004) compared the safety and
efficacy of coadministration with ezetimibe and simvastatin
vs atorvastatin, and found that there was significantly better
LDL-C lowering with ezetimibe/simvastatin 10/10 mg and
10/20 mg (46.1–50.3%) when compared with atorvastatin
10 mg (37.2%) (p ≤ 0.001). Each group reported that the
safety and tolerability of the ezetimibe/simvastatin
combination was similar to statin monotherapy. Importantly,
pharmacokinetic data demonstrate no effect on
concentration maximum (C max) or area under the curve
(AUC) of either drug on the other when coadministered.
In the Vytorin Versus Atorvastatin (VYVA) Study, 1902
patients were randomized to either ezetimibe/simvastatin
or atorvastatin monotherapy (Ballantyne, Abase, et al 2005).
This multicenter, double-blind, 6-week parallel-group study
compared ezetimibe/simvastatin 10/10 mg to 10/80 mg with
atorvastatin 10–80 mg to determine the ability of each dose
to achieve ATP III target LDL-C levels. The ezetimibe/
simvastatin combination achieved greater LDL-C reduction
across the dose ranges (47%–59%) compared with
atorvastatin (36%–53%). Moreover, significantly more
patients at the starting dosage of ezetimibe/simvastatin
10/20 mg achieved their LDL-C goals than did patients at
the starting dose of atorvastatin 10 mg (86.1% vs 69.4%,
p < 0.001). In addition, more CHD and CHD-risk equivalent
patients achieved an LDL-C goal of < 100 mg/dL, as well
as the optional LDL-C of < 70 mg/dL, when treated with
the ezetimibe/simvastatin combination (Table 5). Finally,
the ezetimibe/simvastatin combination provided sig-
nificantly greater raising of HDL-C than atorvastatin (7.9%
vs 4.3%, p < 0.001) while both treatments lowered
triglyceride (TG) values similarly (27.4% vs 25.5%, p- NS).
Recently the EASE (Ezetimibe Add-on to Statin for
Effectiveness) trial determined the benefit of ezetimibe
therapy added to statins vs placebo, which lowered LDL-C
levels and attained ATP III goals (Pearson et al 2005). In a
study of more than 3000 patients, ezetimibe added to statin
achieved an additional 25.8% reduction in LDL-C compared
with a 2.7% reduction with placebo (p < 0.001). Attainment
of ATP III LDL-C goals occurred in 71% of patients who
received add-on ezetimibe compared with 20.6% of patients
who received placebo (p < 0.001).
While the majority of the data regarding the ezetimibe/
simvastatin combination therapy has focused on lipid
efficacy, recent trials have demonstrated a reduction in high-
sensitivity C-reactive protein (hsCRP). While ezetimibe
alone has a modest effect on CRP, Sager et al showed that
the combination of ezetimibe/simvastatin was superior to
simvastatin alone in reducing hsCRP (Sager et al 2005).
To further establish the efficacy and safety of ezetimibe/
simvastatin therapy, as well as determine the effect on CV
outcomes, several randomized clinical trials are underway.
The Study of Heart and Renal Protection (SHARP) study
will evaluate the effects of ezetimibe/simvastatin versus
Table 4 Ezetimibe plus simvastatin versus atorvastatin
LDL LDL
Therapy Dose reduction Therapy Dose reduction
Ezetimibe Study Trial Group
EZE/Sim 10/10 mg 46 % Simva 10 mg 31%
EZE/Sim 10/20 mg 51 % Simva 20 mg 35%
EZE/Sim 10/40 mg 55 % Simva 40 mg 42%
EZE/Sim 10/80 mg 61 % Simva 80 mg 46%
Ballantyne et al (2004)
EZE/Sim 10/10 mg 46% Atorva 10 mg 37%
EZE/Sim 10/20 mg 50% Atorva 20 mg 44%
EZE/Sim 10/40 mg 55% Atorva 40 mg 49%
EZE/Sim 10/80 mg 59% Atorva 80 mg 53%
Vytorin Versus Atorvastatin Study (VYVA)
EZE/Sim 10/10 mg 47% Atorva 10 mg 36%
EZE/Sim 10/20 mg 51% Atorva 20 mg 43%
EZE/Sim 10/40 mg 57% Atorva 40 mg 48%
EZE/Sim 10/80 mg 59% Atorva 80 mg 53%
Abbreviations: LDL-C, low-density lipoprotein cholesterol.
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placebo in 9000 patients with chronic kidney disease. The
Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study
is a placebo-controlled trial to evaluate outcomes in patients
with of aortic stenosis. The Ezetimibe and Simvastatin in
Hypercholesterolemia Enhances Atherosclerotic Regression
(ENHANCE) study will compare ezetimibe/simvastatin
10/80 mg with simvastatin 80 mg on carotid artery disease
by measuring intimal-medial thickness. The study will
recruit 725 men and women with heterozygous familial
hypercholesterolemia. And finally the Improved Reduction
of Outcomes: Vytorin Efficacy International Trial
(IMPROVE IT) will evaluate ezetimibe/simvastatin 10/
40 mg vs simvastatin 40 mg in reducing death and major
coronary events in approximately 10 000 patients with ACS.
Conclusion
Recent evidence-based data suggest that more intensive
lowering of LDL-C, particularly in the high-risk population,
continues to reduce CV risk. Updated guidelines direct
clinicians to achieve lower LDL-C goal levels for their
highest risk patients, which requires the use of more
efficacious statins or combination therapies. Lowering
LDL-C by more than 45%–50% may be required to achieve
the optional LDL-C target of < 70 mg/dL in very high-risk
patients. The ezetimibe/simvastatin combination offers an
effective therapy with a greater likelihood of achieving LDL
goals, and with similar safety, when compared with
equivalent statin monotherapy doses.
Despite the absence of significant evidence-based data
that ezetimibe therapy lowers CV risk, it is important to
point out that other nonstatin clinical trials have shown
significant CV risk reduction in association with lowering
cholesterol. The final report of the Lyon Diet Heart Study
(de Lorgeril et al 1999) found significant CV risk reduction
in patients randomized to the Mediterranean-type diet over
the western-type diet. The Programs on Surgical Control of
the Hyperlipidemias (POSCH) trial (Buchwald et al 1990)
revealed that ileal-bypass surgery lowered LDL-C and was
associated with lower CV event rates. In addition, the
nonstatin pharmacotherapy trial with cholestyramine, the
Lipid Research Clinics – Coronary Primary Prevention Trial
(LRC-CPPT) (LRC 1984) found that patients treated with
cholestyramine significantly reduced their risk of CV events.
While simvastatin has significant outcomes data for CV
risk reduction, there is no significant outcomes data for
ezetimibe. Nonetheless, it would be anticipated that the
enhanced LDL-C lowering capacity of this combination
could result in CHD risk reduction, and endpoint trials in
progress will help to determine this hypothesis.
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LDL-C LDL-C
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